APO-T and LinXis Announce Antibody Drug Conjugate Option to in-License Agreement
Published: Mar 22, 2013
AMERSFOORT & BREDA, the Netherlands--(BUSINESS WIRE)--APO-T B.V. and LinXis B.V., both privately owned oncology companies, announced today that LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates using APO-T’s MAGE-HLA targeted antibodies and LinXis’ unique LX linker technology. In exchange, LinXis will receive milestone payments and royalties. “We are excited to license this program from LinXis, a company known for the development of innovative linker technology for the conjugation of cytotoxic drugs to antibodies. We are convinced by the sound scientific data LinXis has built around its linker program and we believe it to be a valuable addition to our proprietary oncology pipeline. The in-licensing strengthens the company’s development pipeline and its intellectual property base”, said Johan Renes, CEO of APO-T.